Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Aimmune Therapeutics ($AIMT) stock showed an uptick as the company announced the update for its late-stage study of peanut allergy candidate AR101. It reported that in a preliminary dataset of 166 European patients who underwent a food challenge to determine eligibility for the Phase 3 PALISADE trial, 62% (n=103/166) were "reactors" who experienced dose-limiting symptoms. Aimmune Therapeutics believes that the information will  help the company determine the best use of AR101 on a large scale.
The company stock has gained over 37 percent in the past 12 months. Aimmune Therapeutics is involved in the development of treatments for peanut and other food allergies.
<p align="left">

</p>

Shire PLC ($SHPG) announced receiving the FDA approval for its its  MYDAYIS for the treatment of attention deficit hyperactivity disorder in patients at least 13 years old. The drug was earlier known as SHP465and is designed to control symptoms for up to 16 hours. The company expects to launch the drug in the US by next quarter. Its active content are the same as its another ADHD treatment Adderall XR. However, Adderall XR remains effective for only 12 hours. The company’s ADHD drugs Adderall XR and Vyvanse generated close to $2.4 billion in sales last year. The main aim of the new drug is to eliminate the use of short-acting drugs.

<p align="left"><span style="line-height: 1.5;">

</span></p>
&nbsp;

ImmunoCellular Therapeutics ($IMUC) announced suspending patient randomization for its Phase 3 clinical trial assessing lead product candidate ICT-107 for the treatment of newly diagnosed glioblastoma. The company reported the paucity of financial resources as the reason behind the decision. The company also said that it will continue explore strategic alternatives including a merger, reorganization or other business combination.

Cara Therapeutics ($CARA) reported disappointing results from an interim analysis of a Phase 3 clinical trial assessing  IV CR845 for the treatment of post-operative pain in patients undergoing abdominal surgery.  The Independent Data Monitoring Committee recommended that the study continue to test both doses of CR845, which implies that the study has not met its primary endpoint.

Epizyme ($EPZM) announced receiving the Orphan Drug status for its tazemetostat  for the treatment of soft tissue sarcoma. The status offers a seven-year period of market exclusivity for the indication, if approved.

Novo Nordisk ($NVO) reported receiving positive vote by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee that VICTOZA (liraglutide) reduces the risk of major cardiac events in high-risk type 2 diabetics.
<p align="left">

&nbsp;

Soligenix ($SGNX) announced that NIH’s National Institute of Allergy and Infectious Diseases has exercised its option to advance development of RiVax, its ricin toxin vaccine, as a countermeasure to prevent the effects of ricin exposure. The new funding of nearly $2 million will be used for additional animal studies.

Rxi Pharmaceuticals Corporation ($RXII) announced that it has completed the enrollment in its Phase ½ study  assessing RXI-109-1501 for the treatment of patients with advanced neovascular. The primary endpoint of the study is safety and tolerability.
<p align="left">

</p>

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
BTIG Research
Initiates
Abbott Laboratories (ABT)
Buy
$56.00
Low
BMO Capital Markets
Reiterates
Boston Scientific Corporation (BSX)
Buy
$30.00
Low
Wedbush
Reiterates
Catabasis Pharmaceuticals (CATB)
Outperform
$4.00
Low
Cann
Reiterates
Epizyme (EPZM)
Buy
$26.00
N/A
BTIG Research
Initiates
Orthofix International N.V. (OFIX)
Buy
$52.00
Low
Wedbush
Reiterates
Pacira Pharmaceuticals (PCRX)
Outperform
$87.00
Low
Royal Bank Of Canada
Raises Target
Zimmer Biomet Holdings (ZBH)
Outperform
$133.00 -> $140.00
Low

<p align="left">

</span></p>

Gainers (% price change) Last Trade Change Mkt Cap
Arena Pharmaceuticals ARNA 15.75 +1.72 (12.26%) 5.35B
BioDelivery Sciences Intl BDSI 2.60 +0.25 (10.64%) 146.97M
ImmunoGen, Inc. IMGN 5.42 +0.51 (10.39%) 519.16M
Impax Laboratories Inc IPXL 15.75 +1.20 (8.25%) 1.22B
Vanda Pharmaceuticals Inc VNDA 15.20 +1.15 (8.19%) 691.97M
Losers (% price change)
Compugen Ltd. (USA) CGEN 3.60 -0.20 (-5.26%) 188.94M
Cutera, Inc. CUTR 23.85 -1.10 (-4.41%) 353.18M
Endologix, Inc. ELGX 4.62 -0.21 (-4.35%) 399.04M
Community Health Systems CYH 8.81 -0.32 (-3.50%) 1.03B
Amicus Therapeutics, Inc. FOLD 9.55 -0.33 (-3.34%) 1.43B
Most Actives (dollar volume)
PAREXEL Intl. Corp. PRXL 87.04 +3.12 (3.72%) 4.44B
Regeneron Pharmaceuticals REGN 495.33 +23.66 (5.02%) 54.00B
Pfizer Inc. PFE 33.56 +0.34 (1.02%) 201.37B
Gilead Sciences, Inc. GILD 65.59 +0.77 (1.19%) 86.64B
Celgene Corporation CELG 126.22 +1.06 (0.85%) 100.81B

<p align="left">

</p>